Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas (Q47357523)

14 January 2018

title

Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas (English)

1 reference

14 January 2018

1

Wojciech Biernat

1 reference

14 January 2018

author name string

Hervé Huang

2

1 reference

14 January 2018

Hideaki Yokoo

3

1 reference

14 January 2018

Paul Kleihues

4

1 reference

14 January 2018

Hiroko Ohgaki

5

1 reference

14 January 2018

publication date

1 April 2004

1 reference

14 January 2018

published in

Brain Pathology

1 reference

14 January 2018

volume

14

1 reference

14 January 2018

issue

2

1 reference

14 January 2018

page(s)

131-136

1 reference

14 January 2018

Genetics and new approaches to cancer therapy

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

Specific targeting of a mutant, activated FGF receptor found in glioblastoma using a monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

EGF mutant receptor vIII as a molecular target in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

Molecular pathogenesis of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

EGFR gene amplification--rearrangement in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1750-3639.2004.TB00045.X

10.1111/J.1750-3639.2004.TB00045.X

21 January 2018

Identifiers

DOI

1 reference

14 January 2018

PubMed ID

15193025

1 reference

14 January 2018